Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 47 results:
Συντάκτης Τίτλος Τύπος [ Έτος(Asc)]
Φίλτρα: Keyword is Diphosphonates  [Clear All Filters]
2021
Polyzos, S. A., Tournis S., Goulas A., Kollia P., & Whyte M. P. (2021).  Adult hypophosphatasia treated with reduced frequency of teriparatide dosing.. J Musculoskelet Neuronal Interact. 21(4), 584-589.
2019
Fontalis, A., Kenanidis E., Kotronias R. Angelos, Papachristou A., Anagnostis P., Potoupnis M., et al. (2019).  Current and emerging osteoporosis pharmacotherapy for women: state of the art therapies for preventing bone loss.. Expert Opin Pharmacother. 20(9), 1123-1134.
Anagnostis, P., Lambrinoudaki I., Kenanidis E., Potoupnis M., Tsiridis E., & Goulis D. G. (2019).  Drug holidays in osteoporosis treatment: mind the gaps!. Osteoporos Int. 30(12), 2523-2524.
Anagnostis, P., Gkekas N. K., Potoupnis M., Kenanidis E., Tsiridis E., & Goulis D. G. (2019).  New therapeutic targets for osteoporosis.. Maturitas. 120, 1-6.
2018
Anastasilakis, A. D., Tournis S., Yavropoulou M. P., Polyzos S. A., & Makras P. (2018).  Multiple Vertebral Fractures Following Denosumab Discontinuation: Are We Exaggerating?. Calcif Tissue Int. 103(1), 107-108.
Anastasilakis, A. D., Polyzos S. A., & Makras P. (2018).  THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis.. Eur J Endocrinol. 179(1), R31-R45.
2017
Kyrgidis, A., Yavropoulou M. P., Lagoudaki R., Andreadis C., Antoniades K., & Kouvelas D. (2017).  Increased CD14+ and decreased CD14- populations of monocytes 48 h after zolendronic acid infusion in breast cancer patients.. Osteoporos Int. 28(3), 991-999.
2016
Makras, P., Polyzos S. A., & Anastasilakis A. D. (2016).  Letter to the Editor: Bone Turnover as a Potential Determinant of Bone Mineral Density Increase Following the Transition From Bisphosphonates to Either Denosumab or Zoledronic Acid.. J Clin Endocrinol Metab. 101(9), L89-90.
2015
Anastasilakis, A. D., Polyzos S. A., Makras P., Gkiomisi A., Sakellariou G., Savvidis M., et al. (2015).  Circulating semaphorin-4D and plexin-B1 levels in postmenopausal women with low bone mass: the 3-month effect of zoledronic acid, denosumab or teriparatide treatment.. Expert Opin Ther Targets. 19(3), 299-306.
Anastasilakis, A. D., Polyzos S. A., Efstathiadou Z. A., Savvidis M., Sakellariou G. T., Papatheodorou A., et al. (2015).  Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers.. Metabolism. 64(10), 1291-7.
Anastasilakis, A. D., Polyzos S. A., Gkiomisi A., Saridakis Z. G., Digkas D., Bisbinas I., et al. (2015).  Denosumab versus zoledronic acid in patients previously treated with zoledronic acid.. Osteoporos Int. 26(10), 2521-7.
Dounousi, E., Leivaditis K., Eleftheriadis T., & Liakopoulos V. (2015).  Osteoporosis after renal transplantation.. Int Urol Nephrol. 47(3), 503-11.
Papamerkouriou, Y. Mary, Kenanidis E., Gamie Z., Papavasiliou K., Kostakos T., Potoupnis M., et al. (2015).  Treatment of multiple myeloma bone disease: experimental and clinical data.. Expert Opin Biol Ther. 15(2), 213-30.
2014
Anastasilakis, A. D., Polyzos S. A., Makras P., Savvides M., Sakellariou G. T., Gkiomisi A., et al. (2014).  Circulating periostin levels do not differ between postmenopausal women with normal and low bone mass and are not affected by zoledronic acid treatment.. Horm Metab Res. 46(2), 145-9.
2013
Anastasilakis, A. D., Polyzos S. A., Makras P., Gkiomisi A., Savvides M., Papatheodorou A., et al. (2013).  Circulating activin-A is elevated in postmenopausal women with low bone mass: the three-month effect of zoledronic acid treatment.. Osteoporos Int. 24(7), 2127-32.
Anastasilakis, A. D., Polyzos S. A., Gkiomisi A., Bisbinas I., Gerou S., & Makras P. (2013).  Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial.. J Clin Endocrinol Metab. 98(8), 3206-12.
Anagnostis, P., Vyzantiadis T-A., Charizopoulou M., Adamidou F., Karras S., Goulis D. G., et al. (2013).  The effect of monthly ibandronate on bone mineral density and bone turnover markers in patients with haemophilia A and B and increased risk for fracture.. Thromb Haemost. 110(2), 257-63.
2012
Anastasilakis, A. D., Polyzos S. A., Makras P., Sakellariou G. T., Bisbinas I., Gkiomisi A., et al. (2012).  Acute phase response following intravenous zoledronate in postmenopausal women with low bone mass.. Bone. 50(5), 1130-4.
Mitsopoulos, E., Ginikopoulou E., Economidou D., Zanos S., Pateinakis P., Minasidis E., et al. (2012).  Impact of long-term cinacalcet, ibandronate or teriparatide therapy on bone mineral density of hemodialysis patients: a pilot study.. Am J Nephrol. 36(3), 238-44.
Polyzos, S. A., Anastasilakis A. D., Anagnostis P., Kita M., Arsos G., Moralidis E., et al. (2012).  Normal bone turnover markers in a patient with active Paget's disease of bone: response to treatment with zoledronic acid.. Endokrynol Pol. 63(4), 312-5.
Apalla, Z., Tzellos T., Lallas A., Sotiriou E., & Lefaki I. (2012).  Possible zoledronic acid-induced dermatomyositis.. Clin Exp Dermatol. 37(3), 309-11.
Kyrgidis, A., Triaridis S., Kontos K., Patrikidou A., Andreadis C., Constantinidis J., et al. (2012).  Quality of life in breast cancer patients with bisphosphonate-related osteonecrosis of the jaws and patients with head and neck cancer: a comparative study using the EORTC QLQ-C30 and QLQ-HN35 questionnaires.. Anticancer Res. 32(8), 3527-34.
Anastasilakis, A. D., Polyzos S. A., Delaroudis S., Bisbinas I., Sakellariou G. T., Gkiomisi A., et al. (2012).  The role of cytokines and adipocytokines in zoledronate-induced acute phase reaction in postmenopausal women with low bone mass.. Clin Endocrinol (Oxf). 77(6), 816-22.
Galli-Tsinopoulou, A., Kyrgios I., Giza S., Giannopoulou E. Z., Maggana I., & Laliotis N. (2012).  Two-year cyclic infusion of pamidronate improves bone mass density and eliminates risk of fractures in a girl with osteoporosis due to Hajdu-Cheney syndrome.. Minerva Endocrinol. 37(3), 283-9.
2011
Polyzos, N. P., Fatemi H. M., Zavos A., Grimbizis G., Kyrou D., Velasco J-G., et al. (2011).  Aromatase inhibitors in post-menopausal endometriosis.. Reprod Biol Endocrinol. 9, 90.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές